PriceTargets.com logo

X4 Pharmaceuticals - XFOR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.50
  • Forecasted Upside: 372.97%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$0.74 As of 12/1/2023 09:55 PM ET
▼ -0.04 (-5.13%)

This chart shows the closing price for XFOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New X4 Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XFOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XFOR

Analyst Price Target is $3.50
▲ +372.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for X4 Pharmaceuticals in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 372.97% upside from the last price of $0.74.

This chart shows the closing price for XFOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in X4 Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/30/2023B. RileyReiterated RatingBuyLow
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$3.00Low
5/17/2023Stifel NicolausBoost Target$4.00 ➝ $5.00Low
4/10/2023B. RileyLower TargetBuy$7.00 ➝ $3.00Low
3/24/2023OppenheimerLower TargetOutperform$5.00 ➝ $4.00Low
3/22/2023Cantor FitzgeraldReiterated RatingOverweight$3.00Low
3/22/2023HC WainwrightLower TargetBuy$5.00 ➝ $3.00Low
12/22/2022Cantor FitzgeraldInitiated CoverageOverweight$3.00Low
12/11/2022Piper SandlerInitiated CoverageOverweight$3.00Low
11/30/2022HC WainwrightBoost TargetBuy$3.50 ➝ $5.00Low
8/5/2022HC WainwrightLower Target$8.50 ➝ $3.50Low
5/19/2022B. RileyLower TargetBuy$10.00 ➝ $7.00Medium
5/13/2022HC WainwrightLower Target$11.00 ➝ $8.50High
4/5/2022Canaccord Genuity GroupLower TargetBuy$20.00 ➝ $10.00Medium
3/17/2022Stifel NicolausLower Target$19.00 ➝ $10.00Medium
12/14/2021HC WainwrightLower TargetBuy ➝ Buy$21.00 ➝ $11.00High
6/14/2021HC WainwrightReiterated RatingBuy$21.00Medium
6/11/2021Roth CapitalReiterated RatingPositive ➝ Buy$23.00 ➝ $27.00Low
3/22/2021OppenheimerReiterated RatingBuy$16.00High
12/17/2020Brookline Capital ManagementInitiated CoverageBuy$21.00High
11/30/2020B. RileyReiterated RatingBuy$15.00Medium
6/12/2020B. RileyReiterated RatingBuy$15.00Medium
5/8/2020B. RileyLower TargetBuy$19.00 ➝ $15.00Medium
5/8/2020HC WainwrightLower TargetOutperform$22.00 ➝ $21.00Medium
5/7/2020OppenheimerReiterated RatingBuy$20.00Medium
4/12/2020HC WainwrightReiterated RatingBuy$22.00High
3/26/2020CitigroupLower TargetBuy$16.00 ➝ $15.00High
3/13/2020B. RileyLower TargetBuy$25.00 ➝ $19.00Medium
3/12/2020CowenReiterated RatingBuyMedium
2/13/2020Roth CapitalReiterated RatingBuyMedium
1/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
12/23/2019OppenheimerInitiated CoverageOutperform$20.00High
12/18/2019Roth CapitalInitiated CoverageBuy$20.00Medium
12/9/2019CitigroupUpgradeNeutral ➝ Buy$16.00 ➝ $20.00Medium
12/5/2019B. RileyInitiated CoverageBuy$25.00High
10/10/2019CowenReiterated RatingBuyLow
9/30/2019CowenReiterated RatingBuyLow
6/7/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$27.00High
6/5/2019CowenInitiated CoverageOutperform ➝ OutperformLow
(Data available from 12/4/2018 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

X4 Pharmaceuticals logo
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $0.74
Low: $0.70
High: $0.78

50 Day Range

MA: $0.85
Low: $0.71
High: $1.10

52 Week Range

Now: $0.74
Low: $0.65
High: $2.58

Volume

9,716,899 shs

Average Volume

2,258,700 shs

Market Capitalization

$123.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of X4 Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on X4 Pharmaceuticals in the last twelve months: B. Riley, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, and Stifel Nicolaus.
View the latest analyst ratings for XFOR.

What is the current price target for X4 Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for X4 Pharmaceuticals in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 373.0%. Stifel Nicolaus has the highest price target set, predicting XFOR will reach $5.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $3.00 for X4 Pharmaceuticals in the next year.
View the latest price targets for XFOR.

What is the current consensus analyst rating for X4 Pharmaceuticals?

X4 Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XFOR will outperform the market and that investors should add to their positions of X4 Pharmaceuticals.
View the latest ratings for XFOR.

What other companies compete with X4 Pharmaceuticals?

Other companies that are similar to X4 Pharmaceuticals include Acumen Pharmaceuticals, Tenaya Therapeutics, Opthea, Gritstone bio and CEL-SCI. Learn More about companies similar to X4 Pharmaceuticals.

How do I contact X4 Pharmaceuticals' investor relations team?

X4 Pharmaceuticals' physical mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company's listed phone number is (857) 529-8300 and its investor relations email address is [email protected]. The official website for X4 Pharmaceuticals is www.x4pharma.com. Learn More about contacing X4 Pharmaceuticals investor relations.